Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:16248804rdf:typepubmed:Citationlld:pubmed
pubmed-article:16248804lifeskim:mentionsumls-concept:C0020964lld:lifeskim
pubmed-article:16248804lifeskim:mentionsumls-concept:C0041361lld:lifeskim
pubmed-article:16248804pubmed:issue27lld:pubmed
pubmed-article:16248804pubmed:dateCreated2005-10-26lld:pubmed
pubmed-article:16248804pubmed:abstractTextDuring the last decade, a large number of human tumour antigens have been identified. These antigens are classified as tumour-specific shared antigens, tissue-specific differentiation antigens, overexpressed antigens, tumour antigens resulting from mutations, viral antigens and fusion proteins. Antigens recognised by effectors of immune system are potential targets for antigen-specific cancer immunotherapy. However, most tumour antigens are self-proteins and are generally of low immunogenicity and the immune response elicited towards these tumour antigens is not always effective. Strategies to induce and enhance the tumour antigen-specific response are needed. This review will summarise the approaches to discovery of tumour antigens, the current status of tumour antigens, and their potential application to cancer treatment.lld:pubmed
pubmed-article:16248804pubmed:commentsCorrectionshttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:16248804pubmed:languageenglld:pubmed
pubmed-article:16248804pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:16248804pubmed:citationSubsetIMlld:pubmed
pubmed-article:16248804pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:16248804pubmed:statusMEDLINElld:pubmed
pubmed-article:16248804pubmed:issn1381-6128lld:pubmed
pubmed-article:16248804pubmed:authorpubmed-author:ReesRobert...lld:pubmed
pubmed-article:16248804pubmed:authorpubmed-author:HEINHHlld:pubmed
pubmed-article:16248804pubmed:authorpubmed-author:MianShahidSlld:pubmed
pubmed-article:16248804pubmed:authorpubmed-author:AhmadMurriumMlld:pubmed
pubmed-article:16248804pubmed:authorpubmed-author:AliSelman ASAlld:pubmed
pubmed-article:16248804pubmed:authorpubmed-author:McArdleStepha...lld:pubmed
pubmed-article:16248804pubmed:authorpubmed-author:MilesAmandaAlld:pubmed
pubmed-article:16248804pubmed:issnTypePrintlld:pubmed
pubmed-article:16248804pubmed:volume11lld:pubmed
pubmed-article:16248804pubmed:ownerNLMlld:pubmed
pubmed-article:16248804pubmed:authorsCompleteYlld:pubmed
pubmed-article:16248804pubmed:pagination3501-9lld:pubmed
pubmed-article:16248804pubmed:dateRevised2006-11-15lld:pubmed
pubmed-article:16248804pubmed:meshHeadingpubmed-meshheading:16248804...lld:pubmed
pubmed-article:16248804pubmed:meshHeadingpubmed-meshheading:16248804...lld:pubmed
pubmed-article:16248804pubmed:meshHeadingpubmed-meshheading:16248804...lld:pubmed
pubmed-article:16248804pubmed:meshHeadingpubmed-meshheading:16248804...lld:pubmed
pubmed-article:16248804pubmed:year2005lld:pubmed
pubmed-article:16248804pubmed:articleTitleImmunity to tumour antigens.lld:pubmed
pubmed-article:16248804pubmed:affiliationSchool of Biomedical and Natural Sciences, Nottingham Trent University, Clifton Lane, Clifton, Nottingham, NG11 8NS, UK.lld:pubmed
pubmed-article:16248804pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:16248804pubmed:publicationTypeReviewlld:pubmed
pubmed-article:16248804pubmed:publicationTypeResearch Support, Non-U.S. Gov'tlld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:16248804lld:pubmed